Elevance Health Inc. (ELV)

FairStock Score: 53/100 — MIXED

Key Financials

Strengths

• Substantial free cash flow generation of $3.4B provides financial flexibility and dividend capacity
• Diversified revenue streams across Health Benefits, CarelonRx, Carelon Services, and Corporate segments reducing concentration risk
• Low beta of 0.47 suggests relative stability compared to broader market volatility
• Scale and market position with 96,129 employees and $62B market capitalization in essential healthcare services
• Manageable leverage with debt-to-equity ratio of 0.74

Concerns

• Extremely low net margin of 1.10% demonstrates commodity-like business with minimal pricing power and high operational risk
• ROCE of 4.35% far below cost of capital, indicating capital is being destroyed rather than created
• Piotroski F-Score of 3/9 and Altman Z-Score of 1.30 suggest deteriorating financial quality and distress signals
• Stock trading 166% above Graham Number with margin of safety deeply negative
• Negative FCF yield despite $3.4B absolute cash flow indicates valuation stretched relative to capital generation

AI Analysis

Elevance Health presents a classic value trap dressed in statistical cheapness. Yes, the 11.56 P/E appears attractive, but I must look deeper. The Graham Number of $105.33 versus a $280.74 price reveals a margin of safety of negative 166%—a screaming red flag I cannot ignore. The business operates in healthcare insurance, a commoditized industry with razor-thin margins, evidenced by the latest quarter's 1.10% net margin on $49.7B revenue. That's $547 million profit on enormous top-line scale—hardly the economics of a quality business. The ROCE of merely 4.35% is deeply concerning; we're deploying massive capital to generate inadequate returns. The Piotroski F-Score of 3/9 suggests deteriorating financial health, while the Altman Z-Score of 1.30 indicates financial distress territory. The $3.4B free cash flow appears solid, yet the negative FCF yield signals capital intensity. A debt-to-equity of 0.74 is manageable but not insignificant. The ROE of 13.25% is passable but uninspiring. This business lacks the durable competitive moat, pricing power, and capital efficiency I demand. The 52-week range collapse from $458 to $273 reflects market skepticism. I see a mature, cyclical insurance business vulnerable to medical cost inflation, regulatory pressure, and competition—not a compounder worth premium valuations.

Bull Case

Elevance could benefit from operating leverage as healthcare consolidation continues and digital efficiency improvements drive margin expansion. Rising Medicare and Medicaid enrollment alongside employer group stabilization could support revenue growth and improve per-member profitability over time.

Bear Case

Medical cost inflation, regulatory headwinds, and competitive pricing pressure could further compress already-thin margins below 1%. If the company cannot achieve 6%+ ROCE, shareholder returns will remain muted despite buybacks, and debt ratings could face downgrade risk.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer